Model protocol to study pharmacogenomics in inflammatory diseases: Human rheumatoid arthritis

Drug Development Research

Volumn 49, Issue 1, 2000, Pages 29-33

  Attur, Mukundan ^a   Bingham III, Clifton O ^a   Dave, Mandar ^a   Abramson, Steven B ^a,b   Amin, Ashok R ^a,b  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Clinical trials; DMARD; Genomics; NSAIDs; Pharmacogenomics; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; BIOLOGICAL RESPONSE MODIFIER; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID; TUMOR NECROSIS FACTOR RECEPTOR;

ARTHROCENTESIS; ARTICLE; BIOPSY; CELL ISOLATION; CLINICAL PROTOCOL; DRUG MONITORING; DRUG RESEARCH; GENE EXPRESSION; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; LIVER TOXICITY; LUNG TOXICITY; MODEL; MOLECULAR BIOLOGY; NEUTROPHIL; PHARMACOGENOMICS; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SYNOVIUM;

EID: 0034073771     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(200001)49:1<29::AID-DDR5>3.0.CO;2-L     Document Type: Article

References (17)

1. Amin AR, Attur MG, Vyas P, Leszczynska-Piziak J, Levartovsky D, Rediske J, Clancy RM, Vora KA, Abramson SB. 1996. Expression of nitric oxide synthase in human peripheral blood mononuclear cells, neutrophils and T cells. J Inflamm 47:190-205.
2. Amin AR, Attur MG, Patel RN, Thakker GD, Marshall PJ, Rediske J, Abramson SB. 1997. Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage: influence of nitric oxide. J Clin Invest 99:1231-1237.
3. Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M. 1996. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The 1L-1Ra Arthritis Study Group. Arthritis Rheum 39:1092-1101.
4. Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, Breedveld FC, Smolen JS, Eberl G, deWoody K, Feldmann M, Maini RN. 1999. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 163:1521-1528.
5. Hale LP, Haynes BF. 1997. Pathology of rheumatoid arthritis and associated disorders. In: Koopman WJ, editor. Arthritis and allied conditions: a textbook of rheumatology, 13th ed. Baltimore: Williams & Wilkins. p 993-1016.
6. Kavanaugh A, Cohen S, Cush J. 1998. Inhibitors of tumor necrosis factor in rheumatoid arthritis: will that dog hunt? J Rheumatol 25:2049-2053.
7. Maini RN, Elliott MJ, Brennan FM, Williams RO, Chu CQ, Paleolog E, Charles PJ, Taylor PC, Feldmann M. 1995. Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol Rev 144:195-223.
8. McInnes IB, Leung BP, Field M, Wei XQ, Huang FP, Sturrock RD, Kinninmonth A, Weidner J, Mumford R, Liew FY. 1996. Production of nitric oxide in the synovial membrane of rheumatoid and osteoarthritis patients. J Exp Med 184:1519-1524.
9. Melchiorri C, Meliconi R, Frizziero L, Silvestri T, Pulsatelli L, Mazzetti I, Borzi RM, Uguccioni M. Facchini A. 1998. Enhanced and coordinated in vivo expression of inflammatory cytokines and nitric oxide synthase by chondrocytes from patients with osteoarthritis. Arthritis Rheum 41:2165-2174.
10. Moos V, Fickert S, Muller B, Weber U, Sieper J, Bloom L, Ingham KC, Hynes RO. 1999. Immunohistological analysis of cytokine expression in human osteoarthritic and healthy cartilage. J Rheumatol 26:870-879.
11. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, Widmer MB, Blosch CM. 1997. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337:141-147.
12. Nathan C. 1997. Inducible nitric oxide synthase: what difference does it make? J Clin Invest 100:2417-2423.
13. Perkins DJ, St Clair EW, Misukonis MA, Weinberg JB. 1998. Reduction of NOS2 overexpression in rheumatoid arthritis patients treated with anti-tumor necrosis factor alpha monoclonal antibody (cA2). Arthritis Rheum 41:2205-2210.
14. Sakurai H, Kohsaka H, Liu MF, Higashiyama H, Hirata Y, Kanno K, Saito I, Miyasaka N. 1995. Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritides. J Clin Invest 96:2357-2363.
15. St. Claire CE, Wilkinson WE, Lang T, Sanders L, Misukonis MA, Gilkeson GS, Pisetsky DS, Granger DI, Weinberg JB. 1996. Increased expression of blood mononuclear cell nitric oxide synthase type 2 in rheumatoid arthritis patients. J Exp Med 184:1173-1178.
16. Strand V, Tugwell P, Bombardier C, Maetzel A, Crawford B, Dorrier C, Thompson A, Wells G. 1999. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 42:1870-1878.
17. Weinblatt ME, Kremer JM, Coblyn JS, Maier AL, Helfgott SM, Morrell M, Byrne VM, Kaymakcian MV, Strand V. 1999. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 42:1322-1328.